Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Takeda Pharmaceutical Product LIVTENCITY Granted Approval by the FDA

November 25, 2021 0

Takeda Pharmaceutical Granted FDA Approval for LIVTENCITY for Post-Transplant Cytomegalovirus On November 23, 2021 Takeda Pharmaceutical …

The FDA Granted Orphan Drug Designation to Regenxbio Investigational Gene Therapy Drug RGX-202 for Duchenne Muscular Dystrophy

November 23, 2021 0

Regenxbio Granted Orphan Drug Designation for RGX-202 Regenxbio (RGNX) announced the U.S. FDA granted Orphan Drug …

Let’s Talk About 3 Firms with Important News: Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences

November 19, 2021 0

Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences All Have Good News Cassava Sciences & Alzheimer's Disease …

Arcus Biosciences Stock Price Skyrockets Following Gilead Sciences Decision to Augment Their Partnership

November 18, 2021 0

Gilead Sciences Collaboration with Arcus Biosciences Sends Stock Through the Roof There is no doubt that …

GlaxoSmithKline and Vir Biotechnology Announced U.S. Gov’t Contracts to Purchase $1B of Sotrovimab for COVID-19

November 17, 2021 0

GlaxoSmithKline and Vir Biotechnology Announces US Gov't Contracts to Purchase Sotrovimab for COVID-19 GlaxoSmithKline plc (GSK) …

Crispr Therapeutics and ViaCyte Inc to Start Trial of First Gene-Edited Cell Replacement Therapy for Type 1Diabetes

November 16, 2021 0

Crispr Therapeutics and ViaCyte Inc to Start Trial of First Gene-Edited Cell Replacement Therapy CRISPR Therapeutics …

Regenxbio and AbbVie Inc Agreement. See Also: Gilead Sciences and Everest Medicines News

November 12, 2021 0

Regenxbio and AbbVie Inc Agreement Regenxbio (RGNX) announced the successful closure of the collaboration and license …

Merck and Ridgeback Biotherapeutics: U.S. Government to Purchase 1.4 M Additional Courses of Molnupiravir for COVID-19

November 9, 2021 0

U.S. Government to Purchase More of Merck and Ridgeback Biotherapeutics Molnupiravir for COVID-19 Merck (MRK) and …

Reata Pharmaceuticals Third Quarter Financial Results and Other Company Updates

November 8, 2021 0

Reata Pharmaceuticals Business Operations and Clinical Development Updates Reata Pharmaceuticals (RETA) – a clinical-stage biopharmaceutical company …

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at ASH

November 6, 2021 0

Intellia Therapeutics to Present at ASH Intellia Therapeutics (NTLA) announced the presentation of data from its ex …

Sangamo Therapeutics: Preliminary Data Shows Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients with Fabry Disease

November 5, 2021 0

Sangamo Therapeutics Preliminary Results Evaluating Isaralgagene Civaparvovec for Fabry Disease Sangamo Therapeutics (SGMO) announced preliminary results from …

No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences Lead Drug Candidate

November 4, 2021 0

Cassava Science: Journal of Neuroscience Review Shows No Evidence of Data Manipulation Cassava Sciences (SAVA) has been …

Reata Pharmaceuticals Submits MAA to the EMA for Chronic Kidney Disease Caused by Alport Syndrome

October 29, 2021 0

Reata Pharmaceuticals MAA Submission for Bardoxolone Methyl Reata Pharmaceuticals (RETA) announced the submission of a Marketing …

Why Merck’s Stock Price Soared. See Also: Pulmotect Inhaled PUL-042 for Respiratory Symptoms of COVID-19 and Fujirebio Agreement with ADDF

October 28, 2021 0

Merck Stock Soared Great expectations for Merck (MRK) future growth and the future of novel treatments …

Gilead Sciences and Merck Initiate Phase 2 Study Evaluating Lenacapavir and Islatravir for HIV-1

October 26, 2021 0

Gilead Sciences and Merck Collaboration to Develop Long-Acting HIV Treatment Gilead Sciences (GILD) and Merck (MRK) …

Bausch + Lomb and Clearside Biomedical: FDA Approved XIPERE™ for Macular Edema Associated with Uveitis

October 25, 2021 0

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ Bausch + Lomb, a leading …

Agenus Strategic Decision to Withdraw the BLA for Balsitilimab

October 22, 2021 0

Agenus to Withdraw BLA for Balstilimab Agenus (AGEN) announced a strategic decision to withdraw its Biologics …

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001 See Also: Important News from Ultragenyx Pharmaceutical

October 21, 2021 0

Intellia Therapeutics Granted Orphan Drug Designation for NTLA-2001 Intellia Therapeutics (NTLA) announced that the U.S. FDA has …

Reata Pharmaceuticals Announces Presentations Highlighting Clinical Data for Bardoxolone and Disease Education Data on Alport syndrome

October 21, 2021 0

Reata Pharmaceuticals Announcements Reata Pharmaceuticals (RETA) announced that the abstracts highlighting clinical data for bardoxolone methyl …

Rocket Pharmaceuticals Inc Announces Data Updates at the ESGCT Conference for RP-L201 for the Treatment of LAD-I

October 20, 2021 0

Rocket Pharmaceuticals Inc Announces Successful Results at the ESGCT Gene therapy and gene editing plus other …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Takeda Pharmaceutical Product LIVTENCITY Granted Approval by the FDA

The FDA Granted Orphan Drug Designation to Regenxbio Investigational Gene Therapy Drug RGX-202 for Duchenne Muscular Dystrophy

Let’s Talk About 3 Firms with Important News: Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences

Arcus Biosciences Stock Price Skyrockets Following Gilead Sciences Decision to Augment Their Partnership

GlaxoSmithKline and Vir Biotechnology Announced U.S. Gov’t Contracts to Purchase $1B of Sotrovimab for COVID-19

Crispr Therapeutics and ViaCyte Inc to Start Trial of First Gene-Edited Cell Replacement Therapy for Type 1Diabetes

Regenxbio and AbbVie Inc Agreement. See Also: Gilead Sciences and Everest Medicines News

Merck and Ridgeback Biotherapeutics: U.S. Government to Purchase 1.4 M Additional Courses of Molnupiravir for COVID-19

Reata Pharmaceuticals Third Quarter Financial Results and Other Company Updates

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at ASH

Sangamo Therapeutics: Preliminary Data Shows Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients with Fabry Disease

No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences Lead Drug Candidate

Reata Pharmaceuticals Submits MAA to the EMA for Chronic Kidney Disease Caused by Alport Syndrome

Why Merck’s Stock Price Soared. See Also: Pulmotect Inhaled PUL-042 for Respiratory Symptoms of COVID-19 and Fujirebio Agreement with ADDF

Gilead Sciences and Merck Initiate Phase 2 Study Evaluating Lenacapavir and Islatravir for HIV-1

Bausch + Lomb and Clearside Biomedical: FDA Approved XIPERE™ for Macular Edema Associated with Uveitis

Agenus Strategic Decision to Withdraw the BLA for Balsitilimab

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001 See Also: Important News from Ultragenyx Pharmaceutical

Reata Pharmaceuticals Announces Presentations Highlighting Clinical Data for Bardoxolone and Disease Education Data on Alport syndrome

Rocket Pharmaceuticals Inc Announces Data Updates at the ESGCT Conference for RP-L201 for the Treatment of LAD-I